[go: up one dir, main page]

NO961113D0 - Behandling og forebyggelse av prostatakreft - Google Patents

Behandling og forebyggelse av prostatakreft

Info

Publication number
NO961113D0
NO961113D0 NO961113A NO961113A NO961113D0 NO 961113 D0 NO961113 D0 NO 961113D0 NO 961113 A NO961113 A NO 961113A NO 961113 A NO961113 A NO 961113A NO 961113 D0 NO961113 D0 NO 961113D0
Authority
NO
Norway
Prior art keywords
prevention
treatment
prostate cancer
prostate
cancer
Prior art date
Application number
NO961113A
Other languages
English (en)
Other versions
NO961113L (no
Inventor
James Edmund Audia
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/408,745 external-priority patent/US5629007A/en
Priority claimed from US08/407,822 external-priority patent/US5635197A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO961113D0 publication Critical patent/NO961113D0/no
Publication of NO961113L publication Critical patent/NO961113L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO961113A 1995-03-21 1996-03-19 Behandling og forebyggelse av prostatakreft NO961113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/408,745 US5629007A (en) 1995-03-21 1995-03-21 Method of preventing prostatic cancer development
US08/407,822 US5635197A (en) 1995-03-21 1995-03-21 Treatment and prevention of prostatic cancer metastasis

Publications (2)

Publication Number Publication Date
NO961113D0 true NO961113D0 (no) 1996-03-19
NO961113L NO961113L (no) 1996-09-23

Family

ID=27020024

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961113A NO961113L (no) 1995-03-21 1996-03-19 Behandling og forebyggelse av prostatakreft

Country Status (14)

Country Link
EP (1) EP0733365A3 (no)
JP (1) JPH08277220A (no)
KR (1) KR960034202A (no)
AU (1) AU695860B2 (no)
CA (1) CA2172211A1 (no)
CZ (1) CZ287977B6 (no)
HU (1) HUP9600702A3 (no)
IL (1) IL117537A (no)
MX (1) MX9601031A (no)
NO (1) NO961113L (no)
SG (1) SG47093A1 (no)
TW (1) TW450809B (no)
YU (1) YU16196A (no)
ZA (1) ZA962141B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
NZ335512A (en) * 1996-10-30 2001-08-31 Lilly Co Eli Synthesis of benzo[f]quinolinones and intermediates characterised by a process of ketalization by 1,3-bis-trimethylsilyloxy propandiol to a solution of trifluoromethanesulfonate in methylene chloride to yield 6-bromo-2-tetralone propylene ketal
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
CA2338298A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Tricyclic compounds
US6436489B1 (en) 1999-03-24 2002-08-20 Clariant International Ltd. Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures
RU2153358C1 (ru) * 1999-11-10 2000-07-27 Центральный научно-исследовательский рентгенорадиологический институт МЗ России Способ лечения остеолитических метастазов
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
ES2169026T3 (es) * 1991-08-21 2002-07-01 Lilly Co Eli Benzo(f)quinolinonas como inhibidores de 5-alfa-reductasa.

Also Published As

Publication number Publication date
AU4816896A (en) 1996-10-03
IL117537A0 (en) 1996-07-23
SG47093A1 (en) 1998-03-20
CA2172211A1 (en) 1996-09-22
JPH08277220A (ja) 1996-10-22
KR960034202A (ko) 1996-10-22
HUP9600702A2 (en) 1996-12-30
MX9601031A (es) 1997-02-28
AU695860B2 (en) 1998-08-27
EP0733365A3 (en) 1997-03-05
CZ82596A3 (en) 1996-10-16
TW450809B (en) 2001-08-21
ZA962141B (en) 1997-09-15
NO961113L (no) 1996-09-23
CZ287977B6 (cs) 2001-03-14
HU9600702D0 (en) 1996-05-28
YU16196A (sh) 1998-11-05
HUP9600702A3 (en) 1997-04-28
EP0733365A2 (en) 1996-09-25
IL117537A (en) 2001-01-11

Similar Documents

Publication Publication Date Title
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
FI964874A0 (fi) Vihannesten käsittely
NO20002784D0 (no) Forhindring og behandling av amyloidogen sykdom
FI970990A7 (fi) Syövän toteaminen ja hoito
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
ZA965088B (en) Methods of preventing or treating allergles
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
HU9602965D0 (en) Cancer treatment and metastasis prevention
NO955356D0 (no) Behandling av hypotalamisk amenorre
NO965563D0 (no) Behandling og profylakse av osteoporese
NO971900D0 (no) Blandinger og behandling av multippel sklerose
NO20002189D0 (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
NO983512D0 (no) Midler for behandling og forhindring av AIDS
GB9811598D0 (en) Diagnosis and treatment of cancer
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
NO961226L (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO981662D0 (no) Diagnosering av disponerhet for kreft og behandling av dette
NO982888L (no) Sammensetninger og fremgangsmåter for behandling av underjordiske formasjoner
NO981822D0 (no) Anvendelse av proteinet GAX for behandling av cancer
AU5984196A (en) Treatment and prevention of prostatic disease
AU4417996A (en) Treatment of prostate cancer
GB9516572D0 (en) Prevention and/or treatment of disease
AUPO851597A0 (en) Treatment of prostate cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application